NeuroMetrix Reports Publication of Study Demonstrating that NC-stat DPNCheck is Effective at Detecting Diabetic Peripheral

  NeuroMetrix Reports Publication of Study Demonstrating that NC-stat DPNCheck
  is Effective at Detecting Diabetic Peripheral Neuropathy

Business Wire

WALTHAM, Mass. -- March 3, 2014

NeuroMetrix, Inc. (the “Company”) (Nasdaq: NURO), a medical device company
focused on the treatment and management of the neurological complications of
diabetes, today reported publication of results from a study conducted at the
University of Toronto. The study by Lee and colleagues titled “Reliability and
Validity of a Point-of-Care Sural Nerve Conduction Device for Identification
of Diabetic Neuropathy” is available at:

http://www.plosone.org/article/info%3Adoi%2F10.1371%2Fjournal.pone.0086515

NC-stat DPNCheck^® is a fast, accurate and quantitative point-of-care test for
diabetic peripheral neuropathy, or DPN. The DPNCheck test addresses an unmet
medical need for better and more cost-effective screening, diagnosing and
monitoring of DPN. This complication affects over 50% of people with diabetes
and leads to foot ulcers and limb amputation, as well as severe pain and an
overall reduction in patient quality of life.

The study by Lee and colleagues was a single site, blinded comparison of
DPNCheck with gold standard laboratory nerve conduction studies. The study
enrolled 44 subjects with diabetes. Key reported results include:

  *Intra-rater reproducibility of 0.94-0.97 (intra-class correlation
    coefficient)
  *Inter-rater reproducibility of 0.79-0.83 (intra-class correlation
    coefficient)
  *DPNCheck sural nerve amplitude sensitivity of 88% and specificity of 94%
  *DPNCheck sural nerve conduction velocity sensitivity of 94% and
    specificity of 82%
  *Overall DPNCheck test accuracy of 0.88 as quantified by area under the
    receiver operating characteristic (ROC) curve.

The study authors concluded that DPNCheck “… could provide valid nerve
conduction measures that can be used as a confirmatory test for DSP [DPN] with
high reproducibility, acceptable accuracy, and excellent validity.”

“The excellent diagnostic performance of DPNCheck, as reported by Lee and
colleagues, indicates that it is effective at both detecting and ruling-out
DPN. This supports its use for screening as well as conventional diagnostic
testing,” said Shai N. Gozani, M.D., Ph.D., President and Chief Executive
Officer of NeuroMetrix. “Moreover, the study expands the large base of
clinical evidence supporting the effectiveness of NC-stat nerve conduction
measurement technology.”

About NeuroMetrix

NeuroMetrix is a medical device company that develops and markets home use and
point-of-care devices for the treatment and management of chronic pain,
peripheral neuropathies, and associated neurological disorders. The Company is
presently focused on diabetic neuropathies, which affect over 50% of people
with diabetes. If left untreated, diabetic neuropathies trigger foot ulcers
that may require amputation and cause disabling chronic pain. The annual cost
of diabetic neuropathies has been estimated at $14 billion in the United
States. The company markets the SENSUS^™ Pain Management System for treating
chronic pain, focusing on physicians managing patients with painful diabetic
neuropathy. The company also markets the DPNCheck^® device, which is a rapid,
accurate, and quantitative point-of-care test for diabetic neuropathy. This
product is used to detect diabetic neuropathy at an early stage and to guide
treatment. For more information, please visit http://www.DPNCheck.com.

Contact:

NeuroMetrix, Inc.
Thomas T. Higgins, 781-314-2761
SVP and Chief Financial Officer
neurometrix.ir@neurometrix.com
 
Press spacebar to pause and continue. Press esc to stop.